Sandoz Group AG/€SDZ
1D1W1MYTD1Y5YMAX
Capital at risk
About Sandoz Group AG
Sandoz Group AG operates in the pharmaceutical industry, specializing in the development, manufacturing, and distribution of generic medicines and biosimilars. The company's product portfolio includes a wide range of therapeutic areas, such as antibiotics, oncology, and cardiovascular treatments. Sandoz was founded as part of a broader restructuring that involved the separation from Novartis in 2022, with a focus on enhancing the accessibility of high-quality healthcare solutions. Headquartered in Switzerland, Sandoz has a significant global presence with operations spanning across numerous countries. The company emphasizes cost-effective healthcare, leveraging a substantial manufacturing and research capacity to maintain competitive strengths in the global pharmaceutical market.
- Ticker
- €SDZ
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 20,000
- Headquarters
- Basel, Switzerland
- Website
- www.sandoz.com
Sandoz Group AG Metrics
BasicAdvanced
€30B
55.98
€1.27
0.49
€0.87
1.22%
Price and volume
Market cap
€30B
Beta
0.49
52-week high
€81.08
52-week low
€47.01
Average daily volume
923K
Dividend rate
€0.87
Financial strength
Current ratio
1.054
Quick ratio
0.624
Long term debt to equity
0.528
Total debt to equity
0.689
Dividend payout ratio (TTM)
68.89%
Interest coverage (TTM)
5.02%
Profitability
EBITDA (TTM)
1,364.453
Gross margin (TTM)
47.94%
Net profit margin (TTM)
5.53%
Operating margin (TTM)
9.33%
Effective tax rate (TTM)
23.19%
Revenue per employee (TTM)
€502,780
Management effectiveness
Return on assets (TTM)
3.07%
Return on equity (TTM)
7.25%
Valuation
Price to earnings (TTM)
55.977
Price to revenue (TTM)
3.052
Price to book
3.21
Price to tangible book (TTM)
-36.94
Price to free cash flow (TTM)
36.885
Free cash flow yield (TTM)
2.71%
Free cash flow per share (TTM)
1.932
Dividend yield (TTM)
1.22%
Forward dividend yield
1.22%
Growth
Revenue change (TTM)
10.29%
Earnings per share change (TTM)
180.85%
3-year revenue growth (CAGR)
6.89%
3-year earnings per share growth (CAGR)
0.99%
Bulls say / Bears say
Sandoz reported a 9% jump in second-quarter net sales to $3.01 billion, beating consensus expectations, with biosimilar net sales rising 22% at constant currency and accounting for 33% of total sales. (Reuters)
In North America, biosimilars grew 47% at constant currencies in the first half, driven by launches of bone disease drug Wyost and osteoporosis drug Jubbonti, underscoring regional strength. (Reuters)
Sandoz agreed to pay up to $77 million upfront to Shanghai Henlius Biotech for rights to three biosimilars targeting cholesterol, lupus, and colorectal cancer, bolstering its high-value pipeline. (Reuters)
Sandoz now expects its product pricing to decline by a mid-single-digit percentage in 2026, a steeper drop than its previous low-to-mid single-digit forecast, highlighting mounting pricing pressure. (Reuters)
Sandoz filed an anti-dumping complaint with the European Commission over below-cost Chinese imports of the antibiotic ingredient amoxicillin, signalling fierce competition and regulatory challenges in its generics segment. (Reuters)
Management does not expect a material contribution from any potential generic semaglutide launch in 2026, forgoing a significant opportunity in the diabetes and obesity market. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 22 Aug 2026.
Upcoming events
No upcoming events
Funds containing Sandoz Group AG
AllEURGBPUSD
Fund name | Fund size | €SDZ weighting |
|---|---|---|
VanEck World Equal Weight Screened€TSWE | €749M | 0.35% |
VanEck World Equal Weight Screened£TSGB | £651M | 0.35% |
Vanguard FTSE Developed Europe ex UK€VERX | €3.4B | 0.30% |
Vanguard FTSE Developed Europe ex UK£VERX | £2.9B | 0.30% |
Amundi STOXX Europe 600 ESG€C6E | €735M | 0.27% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.